Ziopharm Oncology to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast on February 25, 2021

Rhea-AI Summary

Ziopharm Oncology (Nasdaq: ZIOP) announced a conference call on February 25, 2021, at 4:30 PM EDT to discuss its Q4 and full year 2020 financial results. Investors can access the call by dialing the provided numbers or via the company’s website. Additionally, an R&D Day is scheduled for March 11, 2021, at 11:00 AM EDT, where further details will be shared. Ziopharm is focused on developing non-viral cell and gene therapies to enhance cancer treatment, leveraging collaborations with key research institutions.

Positive

• Scheduled R&D Day on March 11, 2021, may provide future growth insights.
• Strong partnerships with leading institutions like the National Cancer Institute enhance credibility.

Negative

• None.

Company to Hold R&D Day on Thursday, March 11, 2021

BOSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (the “Company”) (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast to discuss financial results for the fourth quarter and full year 2020 on Thursday, February 25, 2021 at 4:30pm EDT.

The live call can be accessed by dialing 1-877-451-6152 (U.S. and Canada) or 1-201-389-0879 (International). The passcode for the conference call is 13715482. The live webcast may be accessed using the link here, or by visiting the “Investors” section of the Ziopharm website at www.ziopharm.com. The call will be recorded and available for replay on the Company’s website for approximately 90 days after the call.

Additionally, the Company announced today that management will host a virtual R&D Day on Thursday, March 11, 2021 at 11:00am EDT. Details for the R&D Day event, including the agenda and guest speakers, will be discussed during the fourth quarter conference call.

About Ziopharm Oncology, Inc.
Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with cancer each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology. Ziopharm’s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic collaborations with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Regeneron Pharmaceuticals. For more information, please visit www.ziopharm.com.

Investor Relations Contact:
Adam D. Levy, Ph.D., MBA
EVP, Investor Relations and Corporate Communications
T: 508.552.9255
E: alevy@ziopharm.com

Media Relations Contact:
Patrick Bursey
LifeSci Communications
T: 646.876.4932
E: pbursey@lifescicomms.com

FAQ

When will Ziopharm Oncology discuss its Q4 2020 financial results?

Ziopharm will discuss its Q4 2020 financial results on February 25, 2021, at 4:30 PM EDT.

What is the significance of the R&D Day planned for March 11, 2021?

The R&D Day on March 11, 2021, will provide insights into Ziopharm's research and development progress.

How can I participate in Ziopharm's conference call?

Investors can participate by calling 1-877-451-6152 for the U.S. or 1-201-389-0879 for international access.

What is Ziopharm Oncology's focus in cancer treatment?

Ziopharm is developing non-viral cell and gene therapies aimed at treating cancer through innovative immuno-oncology approaches.